Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT05423197 | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC | withdrawn | Phase 2 | 0 | Andrei IagaruOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | withdrawn | — | 0 | Cofactor Genomics, Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | withdrawn | Early Phase 1 | 0 | Mitchell MachtayOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT05879484 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | withdrawn | Phase 2 | 0 | Replimune, Inc.INDUSTRY | 8 | Mar 11, 2025 | clinicaltrials |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | withdrawn | Phase 1 | 0 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT03875053 | Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer | withdrawn | N/A | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | Incyte Biosciences International SàrlINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04834349 | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT04922112 | Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado(OSA-HN) | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | withdrawn | Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05743777 | PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma(PROMOTE-HN) | withdrawn | Phase 2 | 0 | Canadian Cancer Trials GroupNETWORK | 0 | May 18, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT02295540 | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 2 | 0 | University of MiamiOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04849377 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | withdrawn | Phase 2 | 0 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT04003025 | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01) | withdrawn | — | 0 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT04266470 | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 / Phase 3 | 0 | MacroGenicsINDUSTRY | 0 | Feb 8, 2022 | clinicaltrials |
| NCT05099952 | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT01967927 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy | withdrawn | Early Phase 1 | 0 | University of ArkansasOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC(ADHERE) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 10, 2021 | clinicaltrials |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | withdrawn | Phase 1 | 0 | Yale UniversityOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Aug 7, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2026source: clinicaltrials